CorMedix has evolved into a profitable, undervalued institutional anti-infectives platform with DefenCath at its core and major upside tied to reimbursement, REZZAYO, and TPN expansion.
Overview
CorMedix has transformed from a clinical-stage biotech into a profitable commercial-stage specialty pharma platform anchored by DefenCath, the only FDA-approved antimicrobial catheter lock solution for hemodialysis patients using central venous catheters. The Melinta acquisition broadened the business into a diversified institutional anti-infectives portfolio and reduced single-product dependency. Q1 2026 revenue surged 226% year over year, supported by strong DefenCath adoption, Medicare reimbursement, and Melinta contributions. The core thesis is rapid commercial scaling, high margins, and major pipeline-driven market expansion.